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Abstract: Myc activation has been implicated in the pathogenesis of
hepatoblastoma (HB), a rare embryonal neoplasm derived from liver
progenitor cells. Here, microRNA (miR) expression proﬁling of 65 HBs
evidenced differential patterns related to developmental stage and
Myc activity. Undifferentiated aggressive HBs overexpressed the
miR-371–3 cluster with concomitant down-regulation of the miR-
100/let-7a-2/miR125b-1 cluster, evoking an ES cell expression pro-
ﬁle. ChIP and Myc inhibition assays in hepatoma cells demonstrated
that both miR clusters are regulated by Myc in an opposite manner.
We show that the two miR clusters exert antagonistic effects on cell
proliferation and tumorigenicity. Moreover, their combined deregu-
lation cooperated in modulating the hepatic tumor phenotype, impli-
cating stem cell-like regulation of Myc dependent miRs in poorly
differentiated HBs. Importantly, a four-miR signature representative
of these clusters efﬁciently stratiﬁed HB patients, and when applied
to 241 hepatocellular carcinomas (HCCs), it identiﬁed invasive
tumors with a poor prognosis. Our data argue that Myc-driven rep-
rograming of miR expression patterns contributes to the aggressive
phenotype of liver tumors originating from hepatic progenitor cells.
 2011 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver.
One of the most common oncogenic events in human cancer
involves the activation of the MYC oncogene. This is not surpris-
ing when it is recognized that MYC may regulate as many as 15%
of genes in the genome from ﬂies to humans [1]. The MYC target
genes are involved in diverse biological programs, such as cell
cycle, cell growth, protein synthesis, cell adhesion and cytoskele-
ton, metabolism, apoptosis, angiogenesis, DNA repair, stem cellJournal of Hepatology 20
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upregulation of six miRs within the miR-17 cluster on chromo-
some 13 through direct binding to the miR-17 locus [2,3] or cause
repression of numerous miRs, including miR-23a/b resulting in
increased glutamine catabolism [4] and let-7 tumor suppressor
regulating expression of MYC itself [5,6]. The involvement of
MYC in control of numerous miRs further expands the class of
critical MYC targets. It is now well recognized that deregulation
of miR expression contributes to cancer development via either
promotion or inhibition of tumorigenesis [7,8]. Furthermore,
since changes in miR expression correlate with tumor character-
istics and clinical course, the therapeutic potential of miRs in can-
cer is currently being explored [9].
The convergence of MYC, miRs, and stem cell biology is ele-
gantly illustrated in a recent article by Buendia and her col-
leagues [10]. The authors proﬁled miR expression in human
hepatoblastoma (HB) and human hepatocelluar carcinoma
(HCC) and investigated the impact of altered miR expression on
tumor biology. Overall the study underscores the value of miR
expression changes for stratiﬁcation of patients with both HB
and HCC.
HB is the most frequent pediatric liver cancer with clear dif-
ferences in etiology and histopathology from HCC, the predomi-
nant form of adult liver cancer. The most notable difference is
that HB develops in the absence of liver disease or viral infection,
leading to the notion that HB might have a genetic or epigenetic
origin. Indeed, the involvement of the Wnt/b-catenin pathway
was shown by the high rate (50–90%) of mutations in CTNNB1
[11]. Buendia and her colleagues have also shown that interaction
of Wnt/b-catenin and Myc signaling is critical in poorly differen-
tiated aggressive HBs [12].
The key ﬁndings of the current paper are the over-expression
of the miR-371–3 cluster and a concomitant down-regulation of
the miR-100/let-7a-2/miR-125b-1 cluster in undifferentiated
aggressive HBs that mimics an ES cell expression proﬁle. The
involvement of MYC in regulating two critical miR clusters in
the opposite manner was demonstrated by ChIP and Myc inhibi-
tion assays in hepatoma cells. Furthermore, the authors showed
that over-expression of the miR-100/let-7a-2/miR-125b-1 cluster
in Huh6 cells delayed tumor occurrence whereas simultaneous
inhibition of miR-371–3 completely blocked tumor formation,
suggesting that antagonistic interplay of the two miR clusters
may decide cancer cell fate. From these data the authors conclude11 vol. 55 j 486–487
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that the combined deregulation of the two miR clusters cooper-
ated in modulating hepatic tumor phenotype, implicating stem
cell-like regulation of Myc-dependent miRs in poorly differenti-
ated HBs. Finally, the authors identiﬁed a four-miR signature rep-
resentative of these clusters (i.e., miR-100, let-7a, miR-371, and
miR-373) that efﬁciently stratiﬁed HB patients, and when applied
to 241 HCCs, it identiﬁed invasive tumors with a poor prognosis.
Based on these data the authors reached a central conclusion that
Myc driven reprograming of miR expression patterns contributes
to the aggressive phenotype of liver tumors originating from
hepatic progenitor cells. Although fully justiﬁed for HB, the situ-
ation may be more complex for HCC. This is well illustrated by
the considerably reduced power of the four-miR signature to sep-
arate the two survival classes (i.e., Cm1 and Cm2; Fig. 5 in the
article) in HCC as compared to HB. The explanation for this differ-
ence may be due in part to the heterogeneous nature of HCC. The
existence of combined hepatocellular-cholangiocarcinoma (CHC),
a histopathologic intermediate form between HCC and cholangi-
ocarcinoma (CC), suggests phenotypic overlap between these
tumor types. This issue has been recently addressed by applying
an integrative oncogenomic approach to address the clinical and
functional implications of the overlapping phenotypes between
HCC and CC [13]. Gene expression proﬁling of human HCC,
CHC, and CC, identiﬁed a novel HCC subtype, i.e., cholangiocarci-
noma-like HCC (CLHCC), which expressed CC-like traits (CC sig-
nature). Similar to CC and CHC, CLHCC showed an aggressive
phenotype with shorter recurrence-free and overall survival. In
addition, CLHCC co-expressed embryonic stem cell-like expres-
sion traits (ES signature) suggesting derivation from bipotent
hepatic progenitor cells. Comparison of CC signature with previ-
ous ES-like, hepatoblast-like, or proliferation-related expression
traits revealed that the prognostic value of the CC signatures
was independent of these signatures. These data emphasize the
critical role of the cell of origin in HCC pathogenesis. The elegant
work by Buendia and her colleagues has signiﬁcantly advanced
our current understanding of the pathogenesis of liver cancer.
How and to what extent the interplay of MYC, miRs, and stem-
ness participate in HCC pathogenesis and heterogeneity remains
to be further explored.Journal of Hepatology 201Conﬂict of interest
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